Women can reduce their risk for womb cancer by eating a Mediterranean diet
the ONA take:
An Italian research team has found that women who eat a Mediterranean diet reduce their risk of womb cancer (endometrial cancer) by more than half.
The researchers reviewed the diets of more than 5,000 women, and measured how the women followed each of nine different components of a Mediterranean diet.
The components included eating lots of vegetables, fruits and nuts, pulses, cereals and potatoes, fish, monounsaturated fats but little meat, milk and other dairy products, and moderate alcohol intake.
The women who adhered most closely to diet reduced their risk by the greatest percentage. Following seven to nine of the components reduced risk of womb cancer by 57%, following six components reduced risk by 46%, and following five components reduced risk by 34%. Following fewer than five components did not significantly reduce a woman’s risk for womb cancer.
Women who eat a Mediterranean diet reduce their risk of womb cancer (endometrial cancer) by more than half.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|